{"id":"higher-bioavailability-bnx-sublingual-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine is a partial agonist at the mu-opioid receptor that provides analgesia and reduces cravings in opioid use disorder. The sublingual tablet formulation with improved bioavailability allows for more efficient absorption through the oral mucosa, bypassing first-pass hepatic metabolism and achieving higher systemic exposure compared to standard formulations.","oneSentence":"BNX is a buprenorphine formulation designed to provide higher bioavailability through sublingual administration, enhancing opioid receptor partial agonism for pain and opioid use disorder treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:22:30.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment)"},{"name":"Moderate to severe pain"}]},"trialDetails":[{"nctId":"NCT01903005","phase":"PHASE4","title":"Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2013-07","conditions":"Opioid Dependence, on Agonist Therapy","enrollment":668}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OX219","Zubsolv","Buprenorphine/naloxone sublingual tablets"],"phase":"marketed","status":"active","brandName":"Higher bioavailability BNX sublingual tablets","genericName":"Higher bioavailability BNX sublingual tablets","companyName":"Orexo AB","companyId":"orexo-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BNX is a buprenorphine formulation designed to provide higher bioavailability through sublingual administration, enhancing opioid receptor partial agonism for pain and opioid use disorder treatment. Used for Opioid use disorder (maintenance treatment), Moderate to severe pain.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-07-03T00:00:00.000Z","mah":"EDENBRIDGE PHARMS","brand_name_local":"ZUBSOLV","application_number":"NDA204242"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2017-11-10T00:00:00.000Z","mah":"Accord Healthcare S.L.U.","brand_name_local":"Zubsolv","application_number":"EMEA/H/C/004407"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}